Pre-pregnancy weight loss intervention with Tirzepatide aims to reduce offspring overweight and adiposity.

Maternal overweight and obesity before and during pregnancy are significant risk factors for adverse offspring health outcomes, including childhood overweight and adiposity. Current interventions often fall short in achieving sustained pre-conceptional weight loss. This study investigates whether a comprehensive pre-conceptional parental weight loss intervention, including pharmacological support, can effectively mitigate these intergenerational health risks by targeting maternal metabolic health, such as insulin resistance and inflammation, and improving incretin responses.

This single-site parallel randomized controlled study will recruit 240 healthy females/couples (prospective mothers with BMI 27-45 kg/m^2, 18-38 years). Participants are randomized 1:1 to either a comprehensive pre-conceptional parental weight loss intervention or a control group, stratified by pre-pregnancy BMI. The intervention targets approximately 10% weight loss over 28 weeks, with adherence to Tirzepatide being a secondary objective. The primary objective is reducing offspring overweight and adiposity at 12 months, along with reducing adverse pregnancy outcomes and neonatal adiposity.